# A Study for Patients With Relapsing Remitting Multiple Sclerosis

> **NCT00869986** · PHASE2,PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 218 (actual)

## Conditions studied

- Relapsing Remitting Multiple Sclerosis

## Interventions

- **DRUG:** dirucotide
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00869986
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2009-09
- **Final completion:** 2009-09
- **Target enrollment:** 218 (ACTUAL)
- **Last updated:** 2010-09-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00869986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00869986, "A Study for Patients With Relapsing Remitting Multiple Sclerosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00869986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*